Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
AimsGlucose-dependent insulinotropic polypeptide (GIP) confers a variety of metabolic benefits in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to investigate the impact of dipeptidyl peptidase 4 (DPP4) inhibitors on GIP levels in T2DM patients.MethodsMedline (PubMed), CENTER (Co...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1203187/full |
| _version_ | 1827867563324866560 |
|---|---|
| author | Shangyu Chai Ruya Zhang Richard David Carr Richard David Carr Carolyn F. Deacon Carolyn F. Deacon Yiman Zheng Swapnil Rajpathak Jingya Chen Miao Yu |
| author_facet | Shangyu Chai Ruya Zhang Richard David Carr Richard David Carr Carolyn F. Deacon Carolyn F. Deacon Yiman Zheng Swapnil Rajpathak Jingya Chen Miao Yu |
| author_sort | Shangyu Chai |
| collection | DOAJ |
| description | AimsGlucose-dependent insulinotropic polypeptide (GIP) confers a variety of metabolic benefits in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to investigate the impact of dipeptidyl peptidase 4 (DPP4) inhibitors on GIP levels in T2DM patients.MethodsMedline (PubMed), CENTER (Cochrane Library), and Embase (Ovid) were searched and randomized controlled trials (RCTs) evaluating the impact of DPP4 inhibitors on fasting and postprandial GIP levels were obtained. For postprandial GIP, only studies with the data of GIP changes reported as the total area under the curve (AUCGIP) using a meal or oral glucose tolerance test were included. A random-effects model was used for data pooling after incorporating heterogeneity.ResultsOverall, 14 RCTs with 541 T2DM patients were included. Compared to placebo/no treatment, the use of DPP4 inhibitors significantly increased the fasting GIP level (standard mean difference [SMD]: 0.77, 95% confidence interval [CI]: 0.48–1.05, P<0.001; I2 = 52%) and postprandial AUCGIP (SMD: 1.33, 95% CI: 1.02–1.64, P<0.001; I2 = 65%). Influence analysis by excluding one dataset at a time showed consistent results. Sensitivity analyses only including studies with radioimmunoassay showed also consistent results (fasting GIP: SMD: 0.75, 95% CI: 0.51–1.00, P<0.001; I2 = 0%; and postprandial AUCGIP: SMD: 1.48, 95% CI: 1.18–1.78, P<0.001; I2 = 54%). Further subgroup analyses demonstrated that the influence of DPP4 inhibitors on fasting and postprandial GIP levels in T2DM patients was not significantly changed by study characteristics such as study design, patient mean age, baseline glycated hemoglobin (HbA1c) concentration, body mass index (BMI), background treatment, treatment duration, or method for postprandial GIP measurement (all P for subgroup effects <0.05).ConclusionThe use of DPP4 inhibitors effectively increases the fasting and postprandial GIP concentrations in T2DM patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022356716. |
| first_indexed | 2024-03-12T15:19:16Z |
| format | Article |
| id | doaj.art-c5d6fcb6c29c4a16a44ab5511b0fe22d |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-12T15:19:16Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-c5d6fcb6c29c4a16a44ab5511b0fe22d2023-08-11T08:49:34ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-08-011410.3389/fendo.2023.12031871203187Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysisShangyu Chai0Ruya Zhang1Richard David Carr2Richard David Carr3Carolyn F. Deacon4Carolyn F. Deacon5Yiman Zheng6Swapnil Rajpathak7Jingya Chen8Miao Yu9Merck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, ChinaMerck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, ChinaHatter Cardiovascular Institute, University College London, London, United KingdomSchool of Biomedical Sciences, Ulster University, Coleraine, United KingdomSchool of Biomedical Sciences, Ulster University, Coleraine, United KingdomDepartment of Biomedical Sciences, University of Copenhagen, Copenhagen, DenmarkMerck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, ChinaMerck Research Laboratories, Merck & Co., Inc., Rahway, NJ, United StatesMerck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, ChinaDepartment of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAimsGlucose-dependent insulinotropic polypeptide (GIP) confers a variety of metabolic benefits in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to investigate the impact of dipeptidyl peptidase 4 (DPP4) inhibitors on GIP levels in T2DM patients.MethodsMedline (PubMed), CENTER (Cochrane Library), and Embase (Ovid) were searched and randomized controlled trials (RCTs) evaluating the impact of DPP4 inhibitors on fasting and postprandial GIP levels were obtained. For postprandial GIP, only studies with the data of GIP changes reported as the total area under the curve (AUCGIP) using a meal or oral glucose tolerance test were included. A random-effects model was used for data pooling after incorporating heterogeneity.ResultsOverall, 14 RCTs with 541 T2DM patients were included. Compared to placebo/no treatment, the use of DPP4 inhibitors significantly increased the fasting GIP level (standard mean difference [SMD]: 0.77, 95% confidence interval [CI]: 0.48–1.05, P<0.001; I2 = 52%) and postprandial AUCGIP (SMD: 1.33, 95% CI: 1.02–1.64, P<0.001; I2 = 65%). Influence analysis by excluding one dataset at a time showed consistent results. Sensitivity analyses only including studies with radioimmunoassay showed also consistent results (fasting GIP: SMD: 0.75, 95% CI: 0.51–1.00, P<0.001; I2 = 0%; and postprandial AUCGIP: SMD: 1.48, 95% CI: 1.18–1.78, P<0.001; I2 = 54%). Further subgroup analyses demonstrated that the influence of DPP4 inhibitors on fasting and postprandial GIP levels in T2DM patients was not significantly changed by study characteristics such as study design, patient mean age, baseline glycated hemoglobin (HbA1c) concentration, body mass index (BMI), background treatment, treatment duration, or method for postprandial GIP measurement (all P for subgroup effects <0.05).ConclusionThe use of DPP4 inhibitors effectively increases the fasting and postprandial GIP concentrations in T2DM patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022356716.https://www.frontiersin.org/articles/10.3389/fendo.2023.1203187/fulldipeptidyl peptidase-4 inhibitorglucose-dependent insulinotropic polypeptidemetabolismrandomized controlled trialsmeta-analysis |
| spellingShingle | Shangyu Chai Ruya Zhang Richard David Carr Richard David Carr Carolyn F. Deacon Carolyn F. Deacon Yiman Zheng Swapnil Rajpathak Jingya Chen Miao Yu Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis Frontiers in Endocrinology dipeptidyl peptidase-4 inhibitor glucose-dependent insulinotropic polypeptide metabolism randomized controlled trials meta-analysis |
| title | Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_full | Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_fullStr | Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_full_unstemmed | Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_short | Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_sort | impact of dipeptidyl peptidase 4 inhibitors on glucose dependent insulinotropic polypeptide in type 2 diabetes mellitus a systematic review and meta analysis |
| topic | dipeptidyl peptidase-4 inhibitor glucose-dependent insulinotropic polypeptide metabolism randomized controlled trials meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1203187/full |
| work_keys_str_mv | AT shangyuchai impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT ruyazhang impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT richarddavidcarr impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT richarddavidcarr impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT carolynfdeacon impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT carolynfdeacon impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT yimanzheng impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT swapnilrajpathak impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT jingyachen impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis AT miaoyu impactofdipeptidylpeptidase4inhibitorsonglucosedependentinsulinotropicpolypeptideintype2diabetesmellitusasystematicreviewandmetaanalysis |